Ryan Sullivan MD

Dr. Ryan J. Sullivan is a clinical and translational investigator whose main areas of interest are the development of novel molecular therapeutic agents for malignant melanoma, the translation of promising preclinical findings into early-stage clinical trials, and the development of predictive biomarkers for these investigational as well as standard treatment approaches.

Sullivan currently serves as the Principal Investigator (PI) of a phase I clinical trials of dabrafenib, trametinib, and navitoclax in patients with advanced melanoma open at the Dana-Farber Harvard Cancer Center (DFHCC) and sponsored by the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP), a phase II clinical trial of the combination of the BRAF inhibitor vemurafenib in combination with high-dose interleukin 2, and serve as the PI on a trial exploring the utility of a novel assay to measure BRAF in the blood.

Dr. Sullivan is board-certified in Medical Oncology and is an Assistant in Medicine and a member of the Center for Melanoma and Teermer Center for Targeted Therapy at MGH, as well as a member of the Melanoma Program at DFHCC. He is also a member of the Dana-Farber/Harvard Cancer Center Institutional Review Board.